glp 1 and liver enzymes Therapeutic Mechanisms Clinical Effects of Glucagon-like Peptide Receptor Agonists in Nonalcoholic Fatty Disease Frontiers | The mechanisms of
Description
Glucagon-like peptide 1 protects pancreatic beta-cells from death by increasing autophagic flux and restoring lysosomal function
The changing nature of how patients access their medication, with the growth of digital pharmacies, home delivery services and healthcare platforms, increases the complexity of temperature-controlled distribution planning
Effective patient advocacy and nuanced clinical documentation remain critical in addressing these persistent coverage inequities
Barkmeier and colleagues compared the effect of multiple antihyperglycemic agentsnamely SGLT-2I, dipeptidyl peptidase-4 (DPP-4), GLP-1RA, and sulfonylureason the need for treatment of diabetic macular edema or PDR in a cohort of 371,698 patients using US claims data
Patients should be advised that they may not have glycemic improvement for 24 weeks after initiating treatment with long-acting GLP-1 receptor agonists
DOI: 10.1038/s41467-017-02488-y Kimura T, Nakagawa K, Kubota H, et al
